Inhibition of the NF-κB pathway dramatically blocked the invasive capacity of lung cancer cells, suggesting that inhibition of S100A4 signaling could effectively mitigate NF-κB-mediated effects. The gene discussed is NFKB1; the disease is lung carcinoma.